JP2016513124A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513124A5 JP2016513124A5 JP2015558976A JP2015558976A JP2016513124A5 JP 2016513124 A5 JP2016513124 A5 JP 2016513124A5 JP 2015558976 A JP2015558976 A JP 2015558976A JP 2015558976 A JP2015558976 A JP 2015558976A JP 2016513124 A5 JP2016513124 A5 JP 2016513124A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt
- pharmaceutical composition
- pharmaceutically acceptable
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 13
- 206010025135 Lupus erythematosus Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 11
- 239000011780 sodium chloride Substances 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 206010003816 Autoimmune disease Diseases 0.000 claims 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 2
- 230000001684 chronic Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 200000000018 inflammatory disease Diseases 0.000 claims 2
- 102000003688 G-protein coupled receptors Human genes 0.000 claims 1
- 108090000045 G-protein coupled receptors Proteins 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 229960003957 Dexamethasone Drugs 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
Description
実施例２の化合物およびデキサメサゾン(Ｄｅｘ)を独立してまたは組み合わせで、上記自然発症エリテマトーデスのＭＲＬ／ｌｐｒマウスモデルによるアッセイで試験し、結果を表１０に示す。実施例２により例示される本発明の化合物およびデキサメサゾンのいずれも、本試験において、１００mg／dLを超えるタンパク質尿素濃度のマウスの低いパーセンテージにより評価して、疾患進行の阻止を示した。本試験において、実施例２の化合物とデキサメサゾンの組み合わせを投与されたマウスは何れも１００mg／mLを超えるタンパク質尿素濃度を示さなかった。
Claims (12)
- 式(Ｉ)
の化合物および／またはその塩。 - Ｒが−ＯＨである、請求項１に記載の化合物またはその塩。
- Ｒが−ＯＰ(Ｏ)(ＯＨ)２である、請求項１に記載の化合物またはその塩。
- 次の構造
- 次の構造
- 結晶性固体である、請求項５に記載の化合物またはその塩。
- 次の構造
- 次の構造
- 請求項２に記載の化合物またはその薬学的に許容される塩および薬学的に許容される担体を含む、医薬組成物。
- Ｇタンパク質共役受容体Ｓ１Ｐ１の活性と関係する疾患または障害を治療するための、請求項１に記載の化合物またはその薬学的に許容される塩を含む医薬組成物であって、哺乳動物患者に該医薬組成物を投与することを特徴とする、医薬組成物。
- 自己免疫性疾患または慢性炎症性疾患を治療するための、請求項１に記載の化合物またはその薬学的に許容される塩を含む医薬組成物であって、哺乳動物患者に該医薬組成物を投与することを特徴とする、医薬組成物。
- 自己免疫性疾患または慢性炎症性疾患が狼瘡、多発性硬化症、炎症性腸疾患およびリウマチ性関節炎から選択される、請求項１１に記載の医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361767531P | 2013-02-21 | 2013-02-21 | |
| US61/767,531 | 2013-02-21 | ||
| PCT/US2014/017534 WO2014130752A2 (en) | 2013-02-21 | 2014-02-21 | Bicyclic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513124A JP2016513124A (ja) | 2016-05-12 |
| JP2016513124A5 true JP2016513124A5 (ja) | 2017-03-16 |
| JP6277210B2 JP6277210B2 (ja) | 2018-02-07 |
Family
ID=50272738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015558976A Active JP6277210B2 (ja) | 2013-02-21 | 2014-02-21 | 二環式化合物 |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US9115054B2 (ja) |
| EP (1) | EP2958888B1 (ja) |
| JP (1) | JP6277210B2 (ja) |
| KR (1) | KR102242265B1 (ja) |
| CN (1) | CN105026362B (ja) |
| AR (1) | AR094851A1 (ja) |
| AU (1) | AU2014218883B2 (ja) |
| BR (1) | BR112015019919A2 (ja) |
| CA (1) | CA2902168C (ja) |
| CL (1) | CL2015002358A1 (ja) |
| CY (1) | CY1118641T1 (ja) |
| DK (1) | DK2958888T3 (ja) |
| EA (1) | EA025294B1 (ja) |
| ES (1) | ES2613262T3 (ja) |
| HK (1) | HK1218111A1 (ja) |
| HR (1) | HRP20170247T1 (ja) |
| HU (1) | HUE031626T2 (ja) |
| IL (1) | IL240613B (ja) |
| LT (1) | LT2958888T (ja) |
| MA (1) | MA38425B1 (ja) |
| MX (1) | MX2015010347A (ja) |
| MY (1) | MY173990A (ja) |
| PE (1) | PE20151746A1 (ja) |
| PH (1) | PH12015501793B1 (ja) |
| PL (1) | PL2958888T3 (ja) |
| PT (1) | PT2958888T (ja) |
| RS (1) | RS55703B1 (ja) |
| SG (1) | SG11201506408TA (ja) |
| SI (1) | SI2958888T1 (ja) |
| SM (1) | SMT201700115B (ja) |
| TN (1) | TN2015000356A1 (ja) |
| TW (1) | TWI613182B (ja) |
| UY (1) | UY35338A (ja) |
| WO (1) | WO2014130752A2 (ja) |
| ZA (1) | ZA201506965B (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015009731A2 (en) | 2013-07-15 | 2015-01-22 | The Regents Of The University Of California | Azacyclic constrained analogs of fty720 |
| MA40082B1 (fr) * | 2014-08-20 | 2019-09-30 | Bristol Myers Squibb Co | Nouveau compose de substitution sphingosine phosphate utile traitement maladie rhumatisme |
| JP6853539B2 (ja) * | 2015-09-24 | 2021-03-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | 合成スフィンゴ脂質様分子、薬物、これらの合成方法、および処置方法 |
| US10633354B2 (en) | 2016-09-02 | 2020-04-28 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| WO2019032632A1 (en) | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | ALKYLPHENYL COMPOUNDS |
| US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
| WO2021062168A1 (en) * | 2019-09-25 | 2021-04-01 | The Regents Of The University Of California | Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| US6069143A (en) | 1994-12-20 | 2000-05-30 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
| AU2003216054B2 (en) | 2002-01-18 | 2007-01-04 | Merck & Co., Inc. | Selective S1P1/Edg1 receptor agonists |
| JP4430941B2 (ja) | 2002-01-18 | 2010-03-10 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体作動薬 |
| US7351725B2 (en) | 2002-01-18 | 2008-04-01 | Merck & Co., Inc. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists |
| CA2477423A1 (en) | 2002-03-01 | 2003-09-12 | Merck & Co., Inc. | Aminoalkylphosphonates and related compounds as edg receptor agonists |
| EP1549640A4 (en) | 2002-06-17 | 2008-08-06 | Merck & Co Inc | 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS |
| AU2004251146A1 (en) | 2003-05-19 | 2005-01-06 | Irm, Llc | Immunosuppressant compounds and compositions |
| WO2005058848A1 (en) | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
| TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| WO2006047195A2 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
| US7754703B2 (en) | 2005-02-14 | 2010-07-13 | University Of Virginia Patent Foundation | Cycloalkane-containing sphingosine 1-phosphate agonists |
| JP2008530197A (ja) | 2005-02-18 | 2008-08-07 | イノディア インク． | ４−ヒドロキシイソロイシンの類似体及びその使用 |
| US8802840B2 (en) | 2005-03-08 | 2014-08-12 | Biota Scientific Management Pty Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
| MX2007011672A (es) | 2005-03-23 | 2007-11-15 | Actelion Pharmaceuticals Ltd | Nuevos derivados de tiofeno como agonistas del receptor de esfingosina-1-fosfato-1. |
| DE602006015297D1 (de) | 2005-04-22 | 2010-08-19 | Daiichi Sankyo Co Ltd | 3-azetidincarbonsäure-derivate zur verwendung als immunsuppressiva |
| JP2008545767A (ja) | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 多環式オキサジアゾールまたはイソキサゾールおよびｓｉｐ受容体リガンドとしてのそれらの使用 |
| AU2006283175A1 (en) | 2005-08-23 | 2007-03-01 | Irm Llc | Immunosuppressant compounds and compositions |
| US20070203111A1 (en) | 2006-01-06 | 2007-08-30 | Sepracor Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
| BRPI0707281A2 (pt) | 2006-01-27 | 2011-04-26 | Univ Virginia | método para prevenção ou tratamento de dor neuropática em um mamìfero |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| CA2646469A1 (en) | 2006-03-21 | 2007-09-27 | Epix Delaware, Inc. | S1p receptor modulating compounds |
| EP2001472A2 (en) | 2006-03-23 | 2008-12-17 | Merck and Co., Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| BRPI0709866B8 (pt) | 2006-04-03 | 2021-05-25 | Astellas Pharma Inc | compostos héteros e composição farmacêutica compreendendo ditos compostos |
| JP2009269819A (ja) | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
| MX2009002234A (es) | 2006-09-08 | 2009-03-16 | Actelion Pharmaceuticals Ltd | Derivados de piridin-3-il como agentes inmunomoduladores. |
| EP2120575A4 (en) * | 2006-12-21 | 2011-04-27 | Abbott Lab | AGONISTS AND ANTAGONISTS OF SPHINGOSINE-1-PHOSPHATE RECEPTORS |
| GB0625648D0 (en) | 2006-12-21 | 2007-01-31 | Glaxo Group Ltd | Compounds |
| US8217027B2 (en) | 2006-12-21 | 2012-07-10 | Abbott Laboratories | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
| CN101610674A (zh) * | 2006-12-21 | 2009-12-23 | 艾博特公司 | 鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物 |
| RU2473545C2 (ru) | 2007-02-02 | 2013-01-27 | Ф.Хоффманн-Ля Рош Аг | Новые 2-аминооксазолины в качестве лигандов taar1 для заболеваний цнс |
| CN101627034B (zh) | 2007-03-16 | 2013-05-15 | 埃科特莱茵药品有限公司 | 氨基-吡啶衍生物作为s1p1/edg1受体激动剂 |
| EA201070422A1 (ru) | 2007-10-04 | 2010-12-30 | Мерк Сероно С.А. | Производные оксадиазола |
| KR20100092473A (ko) | 2007-11-01 | 2010-08-20 | 액테리온 파마슈티칼 리미티드 | 신규한 피리미딘 유도체 |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| ES2431354T3 (es) | 2008-04-01 | 2013-11-26 | Theravance, Inc. | Derivados de 2-aminotetralina como antagonistas del receptor de opioide mu |
| US9181182B2 (en) | 2008-10-17 | 2015-11-10 | Akaal Pharma Pty Ltd | S1P receptors modulators |
| AU2009327133B2 (en) | 2008-12-18 | 2016-04-14 | Merck Serono S.A. | Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis |
| EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| WO2010085581A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases |
| CN102361869A (zh) * | 2009-01-23 | 2012-02-22 | 百时美施贵宝公司 | 在治疗自身免疫性疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物 |
| WO2010085584A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists |
| CA2750125A1 (en) | 2009-02-10 | 2010-08-19 | Abbott Laboratories | Methods for preparing s1p receptor agonists and antagonists |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| EP2592071B1 (en) | 2009-10-29 | 2019-09-18 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
| JP5735634B2 (ja) | 2010-04-23 | 2015-06-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | スフィンゴシン−１−リン酸受容体１アゴニストとしての４−（５−イソオキサゾリルまたは５−ピラゾリル−１，２，４−オキサジアゾール−３−イル）−マンデル酸アミド化合物 |
| CN102260177A (zh) | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 丙二醇类衍生物、其制备方法和其药物组合物与用途 |
| CN102260178A (zh) | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途 |
| EP2595969B1 (en) | 2010-07-20 | 2015-04-22 | Bristol-Myers Squibb Company | Substituted 3-phenyl-1,2,4-oxadiazole compounds |
| WO2012040532A1 (en) | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| JP2013544811A (ja) | 2010-11-03 | 2013-12-19 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および血管疾患の治療用のｓ１ｐ１アゴニストとしての複素環式化合物 |
| WO2012129073A2 (en) | 2011-03-18 | 2012-09-27 | University Of Virginia Patent Foundation | Compositions and methods for tissue engineering and cell based therapies |
| WO2012147311A1 (ja) | 2011-04-26 | 2012-11-01 | パナソニック株式会社 | 暖房システム及び暖房システム制御方法 |
| GB201107325D0 (en) * | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| US9481659B2 (en) | 2011-05-13 | 2016-11-01 | Celgene International Ii Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| AU2013295594B2 (en) | 2012-07-27 | 2018-03-29 | Biogen Ma Inc. | Compounds that are S1P modulating agents and/or ATX modulating agents |
-
2014
- 2014-02-20 US US14/185,164 patent/US9115054B2/en active Active
- 2014-02-20 UY UY0001035338A patent/UY35338A/es unknown
- 2014-02-20 TW TW103105719A patent/TWI613182B/zh not_active IP Right Cessation
- 2014-02-21 RS RS20170188A patent/RS55703B1/sr unknown
- 2014-02-21 EP EP14709822.2A patent/EP2958888B1/en active Active
- 2014-02-21 PE PE2015001795A patent/PE20151746A1/es active IP Right Grant
- 2014-02-21 ES ES14709822.2T patent/ES2613262T3/es active Active
- 2014-02-21 SG SG11201506408TA patent/SG11201506408TA/en unknown
- 2014-02-21 AU AU2014218883A patent/AU2014218883B2/en not_active Ceased
- 2014-02-21 MX MX2015010347A patent/MX2015010347A/es unknown
- 2014-02-21 HU HUE14709822A patent/HUE031626T2/en unknown
- 2014-02-21 JP JP2015558976A patent/JP6277210B2/ja active Active
- 2014-02-21 LT LTEP14709822.2T patent/LT2958888T/lt unknown
- 2014-02-21 SI SI201430106A patent/SI2958888T1/sl unknown
- 2014-02-21 EA EA201591409A patent/EA025294B1/ru not_active IP Right Cessation
- 2014-02-21 CA CA2902168A patent/CA2902168C/en not_active Expired - Fee Related
- 2014-02-21 MA MA38425A patent/MA38425B1/fr unknown
- 2014-02-21 BR BR112015019919A patent/BR112015019919A2/pt not_active Application Discontinuation
- 2014-02-21 PT PT147098222T patent/PT2958888T/pt unknown
- 2014-02-21 MY MYPI2015702746A patent/MY173990A/en unknown
- 2014-02-21 CN CN201480009497.1A patent/CN105026362B/zh active Active
- 2014-02-21 PL PL14709822T patent/PL2958888T3/pl unknown
- 2014-02-21 KR KR1020157025410A patent/KR102242265B1/ko active IP Right Grant
- 2014-02-21 WO PCT/US2014/017534 patent/WO2014130752A2/en active Application Filing
- 2014-02-21 DK DK14709822.2T patent/DK2958888T3/en active
- 2014-02-21 AR ARP140100554A patent/AR094851A1/es unknown
-
2015
- 2015-07-14 US US14/798,498 patent/US9359286B2/en active Active
- 2015-08-14 PH PH12015501793A patent/PH12015501793B1/en unknown
- 2015-08-17 IL IL240613A patent/IL240613B/en active IP Right Grant
- 2015-08-18 TN TN2015000356A patent/TN2015000356A1/en unknown
- 2015-08-21 CL CL2015002358A patent/CL2015002358A1/es unknown
- 2015-09-18 ZA ZA2015/06965A patent/ZA201506965B/en unknown
-
2016
- 2016-05-06 US US15/148,222 patent/US9487481B2/en active Active
- 2016-05-27 HK HK16106055.1A patent/HK1218111A1/zh not_active IP Right Cessation
-
2017
- 2017-02-16 CY CY20171100216T patent/CY1118641T1/el unknown
- 2017-02-16 HR HRP20170247TT patent/HRP20170247T1/hr unknown
- 2017-02-21 SM SM201700115T patent/SMT201700115B/it unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513124A5 (ja) | ||
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| JP2016528301A5 (ja) | ||
| MX2017006483A (es) | Compuestos aminopirazina con propiedades antagonistas a2a. | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| AR088458A1 (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y fingolimod | |
| EA201390821A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты и их применение | |
| EA201101709A1 (ru) | Полициклические антагонисты рецепторов лизофосфатидной кислоты | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| JP2017514910A5 (ja) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| EA201491606A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| JP2016510326A5 (ja) | ||
| JP2017511377A5 (ja) | ||
| RU2017106172A (ru) | Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn) | |
| JP2013518036A5 (ja) | ||
| BR112017017211A2 (pt) | composto, composição, sal farmaceuticamente aceitável de um composto, combinação, formulação farmacêutica, métodos para matar uma micobactéria e/ou inibir a replicação de micobactérias que causam doença em um animal, para tratamento de uma infecção micobacteriana em um animal e para tratamento de uma doença resultante de uma infecção por micobactéria de um mamífero, e, uso de um composto. | |
| JP2014148552A5 (ja) | ||
| BR112015019919A2 (pt) | compostos bicíclicos | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| RU2015135824A (ru) | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 | |
| JP2014513065A5 (ja) | ||
| JP2019052094A5 (ja) | ||
| BR112012022632A2 (pt) | Medicamento compreendendo agonista de ep4 |